<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04512066</url>
  </required_header>
  <id_info>
    <org_study_id>BP41743</org_study_id>
    <nct_id>NCT04512066</nct_id>
  </id_info>
  <brief_title>A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder</brief_title>
  <official_title>A Phase II, Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the efficacy and safety of RO6889450 as monotherapy in&#xD;
      participants experiencing an acute exacerbation of symptoms of schizophrenia or&#xD;
      schizoaffective disorder.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 8, 2020</start_date>
  <completion_date type="Anticipated">April 23, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 23, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score</measure>
    <time_frame>Baseline to Week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with at least 20% or 50% Improvement from Baseline in the PANSS Total Score</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the PANSS Total and Factor Scores</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with at Least 20% or 50% Improvement in the PANSS Factor Scores</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Clinical Global Impression Severity (CGI-S) Scores</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression - Improvement (CGI-I) Scores</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression - Improvement Most Troubling Symptoms (CGI-I MTS)</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Clinical Global Impression - Severity Most Troubling Symptoms (CGI-S MTS)</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from First Randomized Treatment Intake to Readiness for Discharge as Assessed by the Readiness for Discharge Questionnaire (RDQ)</measure>
    <time_frame>Baseline to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs)</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Screening in Electrocardiogram (ECG) Intervals</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Extrapyramidal Symptom Rating Scale (ESRS-A)</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax) of RO6889450</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve at Steady State (AUCss) of RO6889450</measure>
    <time_frame>Baseline to Week 4</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">308</enrollment>
  <condition>Schizophrenia, Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>150 mg Once Daily (QD) RO6889450</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 150 mg of RO6889450 QD for 4 weeks or 12 weeks or 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>45 mg QD RO6889450</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 45 mg of RO6889450 QD for 4 weeks or 12 weeks or 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive oral placebo QD for 4 weeks. Participants from this arm that continue to the extension period will be randomized to either 45 mg or 150 mg QD of RO6889450 for up to an additional 8 weeks or additional 44 weeks (optional 36-Week Safety Extension Phase).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 mg QD Risperidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive 4 mg of risperidone QD for 4 weeks or 12 weeks or 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO6889450</intervention_name>
    <description>Participants will receive oral RO6889450 QD.</description>
    <arm_group_label>150 mg Once Daily (QD) RO6889450</arm_group_label>
    <arm_group_label>45 mg QD RO6889450</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive oral placebo QD.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>Participants will receive oral risperidone QD.</description>
    <arm_group_label>4 mg QD Risperidone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Participant must be 18 to 45 years of age inclusive&#xD;
&#xD;
          -  Participants with a Diagnostic and Statistical Manual of Mental Disorders, Fifth&#xD;
             Edition (DSM-5) diagnosis of schizophrenia or schizoaffective disorder as confirmed by&#xD;
             the Mini International Neuropsychiatric Interview (MINI)&#xD;
&#xD;
          -  Disease duration &lt;/=10 years&#xD;
&#xD;
          -  Have a current acute exacerbation of schizophrenia of no more than 8 weeks before&#xD;
             screening visit and no current signs of apparent lack of treatment response&#xD;
&#xD;
          -  At the time of screening, the participant needs to be either hospitalized or requiring&#xD;
             inpatient psychiatric care according to clinical judgment. If the participant has been&#xD;
             hospitalized for the current exacerbation, the hospitalization has to be of a maximum&#xD;
             of 1 week prior to screening.&#xD;
&#xD;
          -  In previous exacerbations and hospitalizations, the subject has shown a pattern of&#xD;
             response to appropriate antipsychotic treatment&#xD;
&#xD;
          -  Medically stable over a period of 3 months (non-psychiatric conditions) prior to&#xD;
             screening visit and not expected to require hospitalization or change of treatment for&#xD;
             non-psychiatric conditions for the duration of the study&#xD;
&#xD;
          -  Screening and baseline CGI-S &gt;/=4 (moderate or worse)&#xD;
&#xD;
          -  Screening and baseline PANSS total score &gt;= 80&#xD;
&#xD;
          -  Based on screening and baseline PANSS, scores of &gt;/= 4 (moderate or worse) on 2 or&#xD;
             more of the following items: delusions, conceptual disorganization, unusual thought&#xD;
             content, hallucinatory behavior, or suspiciousness/persecution&#xD;
&#xD;
          -  Body mass index between 18 and 35 kg/m2 inclusive&#xD;
&#xD;
          -  Male and female participants; female participants agree to remain abstinent or use&#xD;
             acceptable contraceptive methods during the treatment period and for at least 28 days&#xD;
             after the last dose of study drug&#xD;
&#xD;
        Additional inclusion criteria for optional 36-Week Safety Extension Phase&#xD;
&#xD;
          -  Successful completion of the 12-week treatment period&#xD;
&#xD;
          -  No signs or symptoms of worsening of the psychiatric or medical status that would&#xD;
             preclude the patient from the participation in the 36-Week Safety Extension Phase or&#xD;
             affect their ability to comply with the study requirements.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Has been inpatient for &gt; 1 week or had any other hospitalization for acute&#xD;
             exacerbation of schizophrenia or schizoaffective disorder within the prior 8 weeks or&#xD;
             signs of lack of response to antipsychotic treatment&#xD;
&#xD;
          -  Disease duration &gt; 10 years&#xD;
&#xD;
          -  Is currently an inpatient on an involuntary basis&#xD;
&#xD;
          -  Subject answers &quot;yes&quot; to &quot;Suicidal Ideation&quot; Item 4 (active suicidal ideation with&#xD;
             some intent to act, without specific plan) or item 5 (active suicidal ideation with&#xD;
             specific plan and intent) or any suicidal behavior on the Columbia-Suicide Severity&#xD;
             Rating Scale (C-SSRS) assessment within one month from screening or between screening&#xD;
             and baseline&#xD;
&#xD;
          -  Lifetime history of homicidal behavior&#xD;
&#xD;
          -  Moderate to severe substance use disorder within six months (excluding nicotine) as&#xD;
             defined by DSM-5&#xD;
&#xD;
          -  Other current DSM-5 diagnosis (e.g., bipolar disorder, major depressive disorder)&#xD;
&#xD;
          -  A prior or current general medical condition that might be impairing cognition or&#xD;
             other psychiatric functioning (e.g., migraine headaches requiring prophylaxis&#xD;
             treatment, head trauma, dementia, seizure disorder, stroke; or neurodegenerative,&#xD;
             inflammatory, infectious, neoplastic, toxic, metabolic, or endocrine conditions)&#xD;
&#xD;
          -  Clinically significant abnormalities in laboratory safety test results (including&#xD;
             hepatic and renal panels, complete blood count, chemistry panel and urinalysis),&#xD;
             including a) Aspartate aminotransferase (AST), OR alanine aminotransferase (ALT) 2 x&#xD;
             upper limit of normal (ULN), OR total bilirubin &gt; 1.5 ULN with the exception of known&#xD;
             Gilbert syndrome. b) Serum creatinine &gt; 1.5 ULN&#xD;
&#xD;
          -  Positive result at screening for hepatitis B surface antigen (HBsAg), hepatitis C&#xD;
             virus (HCV, untreated), or human immunodeficiency virus (HIV)-1 and -2. HCV&#xD;
             participants who have been successfully treated and who test negative for HCV RNA are&#xD;
             eligible for entry into the study&#xD;
&#xD;
          -  Tardive dyskinesia that is moderate to severe or requires treatment&#xD;
&#xD;
          -  History of neuroleptic malignant syndrome&#xD;
&#xD;
          -  Average triplicate QTcF interval greater than 450 msec for males and 470 msec for&#xD;
             females or other clinically significant abnormality on screening ECG based on&#xD;
             centralized reading&#xD;
&#xD;
          -  Participant for whom risperidone is contraindicated or who have a documented history&#xD;
             of lack of response or intolerance to risperidone or paliperidone or participants with&#xD;
             known hypersensitivity to risperidone, paliperidone, or to any excipients in Risperdal&#xD;
&#xD;
          -  Participant treated with a long acting injectable antipsychotic or other&#xD;
             antipsychotics that cannot be washed-out within the allotted screening period&#xD;
&#xD;
          -  History of electro-convulsive therapy (ECT) for any reason&#xD;
&#xD;
          -  Participant treated with clozapine at any dose within 12 months of screening visit or&#xD;
             participants treated with clozapine at 200 mg/day or above at any time; low dose (&lt;&#xD;
             200mg/day) use for insomnia or dyskinesia longer than 12 months prior to screening&#xD;
             visit is permitted&#xD;
&#xD;
          -  Participants currently receiving a psychotropic or other medication used as a&#xD;
             psychotropic, which cannot be discontinued during the screening period&#xD;
&#xD;
          -  Positive urine drug screen for amphetamines, methamphetamines, opiates, buprenorphine,&#xD;
             methadone, cocaine and barbiturates. In case of positive urine drug screen for&#xD;
             cannabinoids, the participant may be allowed to enter the study if approved by Medical&#xD;
             Monitor&#xD;
&#xD;
          -  Participant has previously received RO6889450&#xD;
&#xD;
          -  Participant received an investigational drug within 28 days or five times the&#xD;
             half-life of the investigational drug prior to the first study drug administration&#xD;
&#xD;
          -  Diagnosis of COVID-19 infection (confirmed or presumptive) 4 weeks prior to screening&#xD;
             or during screening. Participants can be re-screened after 4 weeks of full recovery in&#xD;
             addition to investigator and/or institutional approval to enroll&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: BP41743 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Woodland International Research Group Inc.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Woodland Research Northwest LLC - ERG - PPDS</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CITrials, Inc.</name>
      <address>
        <city>Bellflower</city>
        <state>California</state>
        <zip>90706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ProScience Research Group</name>
      <address>
        <city>Culver City</city>
        <state>California</state>
        <zip>90230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network, Inc.</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>California Clinical Trials Medical Group managed by Parexel</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synergy San Diego</name>
      <address>
        <city>Lemon Grove</city>
        <state>California</state>
        <zip>91945</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>North County Clinical Research</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>NRC Research Institute</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ASCLEPES Research Centers</name>
      <address>
        <city>Panorama City</city>
        <state>California</state>
        <zip>91402</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CNRI - Los Angeles, LLC</name>
      <address>
        <city>Pico Rivera</city>
        <state>California</state>
        <zip>90660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CITrials, Inc.</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>California Neuropsychopharmacology Clinical Research Institute, LLC</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Artemis Institute For Clinical Research LLC - San Diego - ClinEdge - PPDS</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Schuster Medical Research Institute</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Galiz Research, LLC</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Innovative Clinical Research, Inc.</name>
      <address>
        <city>Lauderhill</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research Institute - Miami - BTC - PPDS</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Centers of America - ERG</name>
      <address>
        <city>Oakland Park</city>
        <state>Florida</state>
        <zip>33334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atlanta Center For Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uptown Research Institute</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Louisiana Clinical Research, LLC</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CBH Health LLC</name>
      <address>
        <city>Gaithersburg</city>
        <state>Maryland</state>
        <zip>20877</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hassman Research Institute - ClinEdge - PPDS</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neuro-Behavioral Clinical Research, Inc.</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Midwest Clinical Research Center - ERG - PPDS</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Community Clinical Research Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78754</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pillar Clinical Research LLC</name>
      <address>
        <city>Garland</city>
        <state>Texas</state>
        <zip>75042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kohnodai Hp., National Center for Global Health and Medicine</name>
      <address>
        <city>Chiba</city>
        <zip>272-8516</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kusatsu Hospital; Psychiatry</name>
      <address>
        <city>Hiroshima</city>
        <zip>733-0864</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nishigahara Hospital</name>
      <address>
        <city>Kita-ku</city>
        <zip>114-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Ryukyu Hospital</name>
      <address>
        <city>Kunigami</city>
        <zip>904-1201</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shironishi Medical Foundation Shironishi Hospital</name>
      <address>
        <city>Matsumoto</city>
        <zip>390-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Center of Neurology and Psychiatry</name>
      <address>
        <city>Tokyo</city>
        <zip>187-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seishinkai Okehazama Hospital Fujita Kokoro Care Center</name>
      <address>
        <city>Toyoake</city>
        <zip>470-1168</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mental Health Research Center of RAMN</name>
      <address>
        <city>Moscow</city>
        <state>Moskovskaja Oblast</state>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leningradskiy Regional Psychoneurologic Dispensary</name>
      <address>
        <city>St-Petersburg</city>
        <state>Sankt Petersburg</state>
        <zip>188820</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Psychiatry Hospital #1 n.a. P.P.Kashchenko</name>
      <address>
        <city>St. Petersburg</city>
        <state>Sankt Petersburg</state>
        <zip>188357</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Psychiatric Hospital St Nicholas the Wonderworker</name>
      <address>
        <city>St. Petersburg</city>
        <state>Sankt Petersburg</state>
        <zip>190121</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>City Psychiatry Hospital #3 n.a. I.I. Skvortsov-Stepanov</name>
      <address>
        <city>St. Petersburg</city>
        <state>Sankt Petersburg</state>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>FSBI National Medical Research Centre of Psychiatry and Neurology n.a. V.M. Bekhterev of MoH of RF</name>
      <address>
        <city>Sankt-peterburg</city>
        <state>Vladimir</state>
        <zip>192019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saratov regional clinical psychoneurological hospital St Sofii</name>
      <address>
        <city>Saratov</city>
        <zip>410060</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stavropol Regional Psychiatry Hospital #2</name>
      <address>
        <city>Stavropol</city>
        <zip>357034</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tomsk National Scientific Medical Center of Russian Academy of Sciences</name>
      <address>
        <city>Tomsk</city>
        <zip>634009</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Communal Non-Commercial Enterprise of Kharkiv RC Regional clinical psychiatric hospital #3</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkiv Governorate</state>
        <zip>61068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Public NPE Kherson Regional Institution of Mental Care of Kherson RC</name>
      <address>
        <city>Kherson</city>
        <state>Kherson Governorate</state>
        <zip>73488</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Municipal Non-Commercial Enterprise Odesa RMC for Mental Health of Odessa Regional Council</name>
      <address>
        <city>Odesa</city>
        <state>Kherson Governorate</state>
        <zip>65006</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyiv Medical Regional Union Psychiatry</name>
      <address>
        <city>Kylv</city>
        <state>KIEV Governorate</state>
        <zip>04080</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Communal Non-Commercial Enterprise Cherkasy Regional Psychiatric Hospital of Cherkasy RC</name>
      <address>
        <city>Smila</city>
        <state>KIEV Governorate</state>
        <zip>20708</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Communal NPE Vinnytsia Reg. Clin. Psychoneurolog. Hosp. n.a. O.I. Yushchenko of Vinnytsia RC</name>
      <address>
        <city>Vinnytsia</city>
        <state>Podolia Governorate</state>
        <zip>21037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Communal NPE Vinnytsia Reg. Clin. Psychoneurolog. Hosp. n.a. O.I. Yushchenko of Vinnytsia RC</name>
      <address>
        <city>Vinnytsia</city>
        <state>Podolia Governorate</state>
        <zip>21037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Poltava Regional Psychiatry Hospital</name>
      <address>
        <city>Poltava</city>
        <state>Poltava Governorate</state>
        <zip>36030</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Communal Nonprofit enterprise Ternopil Regional Clinical Psychoneurological Hospital of TRC</name>
      <address>
        <city>Ternopil</city>
        <state>Volhynian Governorate</state>
        <zip>46027</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 12, 2020</study_first_submitted>
  <study_first_submitted_qc>August 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2020</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

